C11380: Novel Biological Countermeasure Against Toxic Nerve AgentsNovelty:
The technology comprises a novel recombinant butyrlcholinesterase (BChE) protein that is long lived and has the same properties as those of plasma derived natural BChE protein.
Value Proposition:
Currently, the short lived recombinant BChE protein and its other inferior properties limit the use of existing recombinant gene expression systems in the war against toxic organophosphorus (OP) nerve agents. This technology allows the production of a novel recombinant protein with equivalent physical, chemical and biological properties as the plasma-derived natural human BChE protein – far superior to other recombinant proteins available in the market. The benefits of the invention include:
• Long-lived and active recombinant BChE protein.
• Equivalent physical, chemical and biological properties as the plasma-derived human BChE.
• The engineered expression system can be applicable to the production of numerous other OP-bioscavengers.
Technical Details:
Johns Hopkins researchers have devised a new recombinant gene expression system for the production of an optimized recombinant BChE protein, a prophylactic used to inhibit the action of OP nerve agents such as Sarin and VX. The invention comprises the engineering of Chinese Hamster Ovary cells for the production of near-native recombinant BChE protein resulting in an increased circulatory lifetime of the recombinant protein.
Looking for Partners:
To develop & commercialize the technology as an efficient biological tool to treat and prevent the action of OP nerve agents.
Stage of Development:
Pre-Clinical
Data Availability:
Under NDA/CDA
Publications/Associated Cases:
Not available at this time
